News

Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas

WARREN, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today provided additional guidance on the first clinical product of the company's proprietary ExacTcell™ technology, TVGN 489, designed to treat SARS-CoV-2 infections in immunocompromised oncology patients, and a subgroup of patients with post-acute sequelae of SARS-CoV-2 (PASC).

10/25/2024

Tevogen Bio's Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development

WARREN, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announces its Artificial Intelligence effort, Tevogen AI, has joined Microsoft (Nasdaq: MSFT) for Startups. This partnership marks a significant milestone for Tevogen, providing unparalleled access to Microsoft's extensive ecosystem. The partnership is set to accelerate and streamline the development of Tevogen's proprietary algorithms, significantly advancing our mission to lower the total cost of drug development, expedite drug discovery, and deliver life-changing therapies to large patient populations.

10/23/2024

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Tevogen Bio Holdings Inc. (TVGN) a buy, sell, or hold?

Tevogen Bio Holdings Inc. (TVGN) can sell. Click on Rating Page for detail.

What is Tevogen Bio Holdings Inc.'s stock price?

The price of Tevogen Bio Holdings Inc. (TVGN) is 2.549 and it was updated on 2024-10-29 13:00:43.

Is Tevogen Bio Holdings Inc. (TVGN) overvalued or undervalued?

Currently Tevogen Bio Holdings Inc. (TVGN) is in undervalued.

News

From:

To:

News
Tevogen Bio To Provide Timelines Associated with Recently Announced Revenue Forecast and Updates on Operational Readiness This Week WARREN, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, plans to provide further updates on the previously announced revenue forecast for Tevogen Oncology and Tevogen Specialty Care therapeutic areas by the end of this week. The revenue forecast for the two therapeutic areas is approximately $1 billion each in their respective launch years. The 5-year combined estimate for the two therapeutic areas is between $28 billion and $36 billion. Tue, Oct. 22, 2024
Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion WARREN, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced its top-line revenue forecast for its specialty care pipeline, projecting nearly $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $18 billion and $22 billion. This forecast reflects the company's unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come. Mon, Oct. 21, 2024
Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming Days WARREN, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, reported last week that Chief Scientific Officer (CSO) Dr. Neal Flomenberg sold shares. Tevogen's Chief Financial Officer, Kirti Desai, clarified that the sale was made solely to satisfy the payment of tax obligations relating to the vesting of restricted stock units and was not made at the discretion of the CSO. Mon, Oct. 21, 2024
Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company's Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days WARREN, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN) is a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers. Fri, Oct. 18, 2024
Why Is Small-Cap Tevogen Bio Stock Rocketing Higher On Thursday? On Thursday, Tevogen Bio Holdings Inc. TVGN announced its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $10 billion and $14 billion. Thu, Oct. 17, 2024

SEC Filings

SEC Filings
Tevogen Bio Holdings Inc. (TVGN) - 4 SEC Filings 10/18/2024
Tevogen Bio Holdings Inc. (TVGN) - 8-K/A - Current report SEC Filings 08/26/2024
Tevogen Bio Holdings Inc. (TVGN) - 424B3 SEC Filings 08/26/2024
Tevogen Bio Holdings Inc. (TVGN) - 8-K - Current report SEC Filings 08/23/2024
Tevogen Bio Holdings Inc. (TVGN) - 424B3 SEC Filings 08/23/2024
Tevogen Bio Holdings Inc. (TVGN) - 424B3 SEC Filings 08/14/2024
Tevogen Bio Holdings Inc. (TVGN) - 10-Q - Quarterly Report SEC Filings 08/14/2024
Tevogen Bio Holdings Inc. (TVGN) - EFFECT SEC Filings 08/05/2024
Tevogen Bio Holdings Inc. (TVGN) - 424B3 SEC Filings 08/05/2024
Tevogen Bio Holdings Inc. (TVGN) - S-1/A SEC Filings 08/01/2024
Tevogen Bio Holdings Inc. (TVGN) - S-1/A SEC Filings 07/23/2024

Press Releases

StockPrice Release
Tevogen bio signs letter of intent with cd8 technology to build up to a $50 million r&d and manufacturing facility; no impact on shareholder equity 10/29/2024
Tevogen bio provides additional guidance on introduction of t cell therapy for oncology and specialty care therapeutic areas 10/25/2024
Tevogen bio's effort in artificial intelligence, tevogen ai, joins microsoft for startups, begins accelerating drug development 10/23/2024
Tevogen bio to provide timelines associated with recently announced revenue forecast and updates on operational readiness this week 10/22/2024
Tevogen bio specialty care reports top-line revenue forecast of nearly $1 billion in launch year and cumulative 5-year estimate between $18 billion and $22 billion 10/21/2024
Tevogen bio provides clarity on cso share sales to satisfy tax obligations, expects additional forecast and progress updates in the coming days 10/21/2024
Tevogen ceo expresses gratitude for unprecedented public support of company's business model of commercial success through patient accessibility and reaffirms his commitment to share additional details in the coming days 10/18/2024
Tevogen bio oncology reports top-line revenue forecast of $1 billion in launch year and cumulative 5-year estimate between $10 billion and $14 billion; forecasts for non-oncology therapeutic areas to follow 10/17/2024
Tevogen investors congratulate on prestigious recognition of pioneering biopharma business model, breakthrough innovations, building assets estimated to exceed $10 billion 10/17/2024
Tevogen bio takes lead in developing cell therapies designed to eradicate post procedure human papilloma virus in women with precancerous cervical lesions 10/15/2024
Tevogen bio highlights the publication of promising trial data as the ceo expresses optimism about the company's scientific breakthrough in mainstreaming cell therapy through a new class of off-the-shelf t-cell therapies, manufactured and stored for immediate use 10/15/2024
Tevogen ceo reaffirms the company's commitment to closing the information gap on its multi-billion-dollar assets, following the release of revenue projections 10/14/2024
Tevogen bio plans to share $1b+ revenue potential of its pipeline portfolio beginning week of october 14, 2024 10/11/2024
Tevogen bio extends pipeline prioritizing oncology and long covid 10/11/2024
Tevogen bio highlights promising trial data as ceo leads patient advocacy at capitol hill, pledging to leverage multi-billion dollar company assets to combat long covid and spearhead a new wave of medical innovation 10/08/2024
Tevogen bio leadership meets members of u.s. congress to advocate for long covid patients and highlights achievements and assets as a blueprint for biotech innovation 09/24/2024
Correction – tevogen bio reports second quarter 2024 financial results, eliminates doubt about company's ability to continue as a going concern, eliminates series b preferred shares 08/15/2024
Tevogen bio reports second quarter 2024 financial results, eliminates doubt about company's ability to continue as a going concern, eliminates series b preferred shares 08/15/2024
Tevogen bio's innovation and public health advisory board chairperson, professor sten vermund, appointed dean of the university of south florida health college of public health 08/14/2024
Tevogen bio's founding ceo, ryan saadi, expresses conviction in company's growth strategy and reaffirms newly effective form s-1 does not relate to previously undisclosed new issuance of dilutive securities 08/09/2024
Tevogen bio issues letter to stockholders highlighting recent achievements, growth plans, and consideration of a potential share buyback 07/11/2024
Tevogen bio's r&d leadership discusses the promise of its genetically unmodified, off-the-shelf t cell technology for the treatment of infectious diseases, cancers, and neurological disorders with nasdaq's kristina ayanian 07/10/2024
Ryan saadi congratulates marc benioff on receiving the yale legend in leadership award and commends yale school of management for recognizing the importance of integrating corporate success with social responsibility 07/08/2024
Tevogen bio files registration statement for previously disclosed securities; does not relate to any previously undisclosed new issuances of dilutive securities 06/26/2024
Tevogen bio announces publication of positive phase i clinical trial results for tvgn 489 in blood advances 06/25/2024
Tevogen.ai head discusses company's bold strategy to shape the future of t cell therapies at longwood spring mit conference 06/18/2024
Tevogen bio set to join russell 3000® index 06/12/2024
Tevogen bio enters into agreement for up to $50 million in financing to advance r&d and clinical development efforts 06/11/2024
Correction – tevogen bio expresses gratitude to patients, first responders, elected officials, and members of the united states congress for attending its inaugural post-public listing social engagement event 06/07/2024
Tevogen bio expresses gratitude to patients, first responders, elected officials, and members of the united states congress for attending its inaugural post-listing social engagement event 06/06/2024
Tevogen bio confirms ongoing efficacy of tvgn 489, its investigational allogeneic off-the-shelf immunotherapy, against dominant flirt strains of sars-cov-2 06/06/2024
Tevogen bio reports first quarter 2024 financial results 05/29/2024
Tevogen bio appoints former police chief & fbi national academy graduate, william keane, as vice president of strategic initiatives 05/16/2024
Tevogen bio announces up to $50 million in financing to further advance operational objectives 05/10/2024
Tevogen bio announces full year 2023 financial results and upcoming operational objectives 05/01/2024
Tevogen bio ceo highlights expected reporting of a $94.9 million liability elimination, ai initiative, and leadership appointments 04/26/2024
Tevogen bio's chief scientific officer speaks on the harnessing of cytotoxic t lymphocytes (ctls) to target cancers 04/11/2024
Tevogen bio appoints tapan v shah as head of investor relations and corporate development 04/03/2024
Tevogen bio reports series a-1 preferred stock investment at $10 conversion price 03/28/2024
Tevogen bio announces series a-1 preferred stock investment 03/27/2024
Tevogen bio reports its investigational sars-cov-2 specific t cell therapy, tvgn-489, retains activity against the dominant jn.1 variant 03/20/2024
Tevogen bio holdings congratulates its board member and esteemed global safety management expert, victor sordillo, on his appointment as managing director of risk advisory services at verita 03/05/2024
Mittul mehta, head of tevogen's artificial intelligence initiative tevogen.ai, emphasizes importance of proactive talent development for biopharmaceutical sector to allow rapid adoption of ai 02/27/2024
Cell therapy company tevogen bio holdings inc. prepares to launch crucial genetic predisposition study in preparation to investigate the potential of tvgn 489 to address critical unmet need for long covid treatment 02/21/2024
Cell therapy company tevogen bio holdings inc. (nasdaq: tvgn) rings opening bell at nasdaq exchange on february 15th, 2024, begins public trading on the open market 02/17/2024
Tevogen bio announces $8 million equity investment 02/15/2024

More Headlines

News
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow WARREN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $10 billion and $14 billion. This forecast reflects the company's unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come. 10/17/2024
Tevogen Investors Congratulate on Prestigious Recognition of Pioneering Biopharma Business Model, Breakthrough Innovations, Building Assets Estimated to Exceed $10 Billion WARREN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- HMP Partners and The Patel Family LLP, leading investors in innovative healthcare ventures, congratulate Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN) and founding CEO Dr. Ryan Saadi for being honored with prestigious proclamation by the Township of Warren, New Jersey, in recognition of their Nobel Prize nomination for pioneering business model to alleviate health inequality through breakthrough life-saving medical innovations. 10/17/2024
Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions WARREN, N.J., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, elaborates on developing TVGN 920, a T cell therapy for the treatment of HPV in women with precancerous cervical lesions. 10/15/2024
Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company's Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use WARREN, N.J., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today highlights the publication of its phase I clinical trial data of TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy, published by the journal Blood Advances in August of this year. 10/15/2024
Tevogen CEO Reaffirms the Company's Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue Projections WARREN, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, plans to update shareholders on multi-billion dollar asset valuation following this week's $1b+ revenue potential announcement. 10/14/2024
Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024 WARREN, N.J., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, plans to share its $1B+ revenue potential, a reflection of the company's novel business approach. 10/11/2024
Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID WARREN, N.J., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announces updates on its growing therapeutic pipeline, designed to meet the high unmet needs of cancer patients. The company is pursuing a prudent commercialization strategy with a focus on its ExacTcell™ technology platform, which leverages precision T cell therapies to address supportive care for cancer patients. 10/11/2024
Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Medical Innovation WARREN, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today reissues its previously announced topline results from its Proof-of-Concept (POC) clinical trial designed to evaluate the safety and feasibility of TVGN 489, the company's first clinical product utilizing the internally developed ExacTcell™ technology, for the treatment of acute high-risk SARS-CoV-2 patients. TVGN 489 is a genetically unmodified, off-the-shelf, allogeneic cytotoxic CD8+ T lymphocyte (CTL) product with precise targets across the SARS-CoV-2 genome, not just the Spike protein. To date, TVGN 489 targets, identified early in the pandemic, persist in the most recent SARS-CoV-2 variants. The open label comparative trial was conducted at Thomas Jefferson University Hospital in Philadelphia to assess the safety and feasibility of TVGN 489 when given at one of four escalating doses. Twelve ambulatory patients with newly diagnosed SARS-CoV-2 infection who were at higher risk for infection-related complications due to advanced age or CDC-defined comorbid conditions such as heart, lung, liver, and kidney disease, hypertension, diabetes, cancer, or obesity were treated on the trial. Eighteen patients, who also met these criteria but did not receive TVGN 489 because of lack of HLA matching, were enrolled on an observational arm in the study and treated with standard of care including monoclonal antibodies. 10/08/2024
Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation WARREN, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, shared the company's ambition to address the Long COVID crisis as its leadership met with Congress on Capitol Hill last week. 09/24/2024
CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares WARREN, N.J., Aug. 15, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Tevogen Bio Inc (Nasdaq: TVGN), please note that paragraph two has been updated. 08/15/2024
Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares WARREN, N.J., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has announced financial results for the fiscal quarter ending June 30, 2024, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission. 08/15/2024
Tevogen Bio's Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health WARREN, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holding Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, congratulates Professor Sten Vermund, MD, PhD, Chairperson of Tevogen Bio's Innovation and Public Health Advisory Board, on being named as the dean of the USF Health College of Public Health, effective January 1, 2025. 08/14/2024
Tevogen Bio's Founding CEO, Ryan Saadi, Expresses Conviction in Company's Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities WARREN, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, filed a Registration Statement on Form S-1 (File No. 08/09/2024
Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback WARREN, N.J., July 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holding Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, today released a letter to stockholders highlighting recent achievements, growth plans, and consideration of a potential share buyback. 07/11/2024
Tevogen Bio's R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian WARREN, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Dr. Neal Flomenberg and Dr. Lori Grosso of Tevogen Bio Holding Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, discussed the promise of T cell therapy and Tevogen's mission to make it mainstream on Nasdaq's broadcast, Live From MarketSite with Kristina Ayanian. 07/10/2024
Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility WARREN, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, founding CEO of Tevogen Bio (“Tevogen”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, congratulates Salesforce CEO Marc Benioff on receiving the Yale Legend in Leadership Award for highlighting that business success must coexist with social prosperity at the bi-annual CEO Summit. The Yale Legend in Leadership Award was created 35 years ago to honor current and former CEOs who serve as living legends to inspire chief executives across industries, sectors, and nations. 07/08/2024
Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities This new registration statement does not relate to any previously undisclosed new issuances of dilutive securities. Includes issuance of shares underlying warrants originally issued in 2021, earnout shares previously registered on recent Registration Statement on Form S-4, and the resale of shares that are outstanding or issuable under previously disclosed securities. 06/26/2024
Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances WARREN, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, reports publication of its phase I clinical trial data of TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy by the journal Blood Advances. 06/25/2024
Tevogen.AI Head Discusses Company's Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, highlights the commentary of Mittul Mehta, Tevogen's Chief Information Officer and Head of Tevogen.AI, at the Longwood Spring MIT Conference. 06/18/2024
Tevogen Bio Set to Join Russell 3000® Index WARREN, N.J., June 12, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. 06/12/2024
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts Includes $36 million line of credit and potential $14 million private placement WARREN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, following the recent elimination of $94.9 million in balance sheet liabilities, has entered into a definitive agreement for up to $50 million in financing. 06/11/2024
CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event WARREN, N.J., June 07, 2024 (GLOBE NEWSWIRE) -- A release was issued under a similar headline on Thursday, June 6th by Tevogen Bio Holdings Inc. (Nasdaq: TVGN). 06/07/2024
Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event WARREN, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes (“CD8+ CTLs”), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders with the aim of addressing the significant unmet needs of large patient populations. 06/06/2024
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2 Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2 06/06/2024
Tevogen Bio Reports First Quarter 2024 Financial Results Confirms liability elimination of $94.9 million and discloses $11.3 million of net income Reports net cash used for operating activities was $2.1 million Reiterates commitment to both patients and shareholders WARREN, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has announced financial results for the fiscal quarter ended March 31, 2024, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission. 05/29/2024
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives WARREN, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, announces the appointment of William Keane as Vice President of Strategic Initiatives. 05/16/2024
Why Is Tevogen Bio (TVGN) Stock Up 54% Today? Tevogen Bio (NASDAQ: TVGN ) stock is rocketing higher on Monday after announcing an agreement that secures it an additional $50 million in financing. The clinical-stage specialty immunotherapy biotech company entered into a binding term sheet with one of its existing investors for these funds. 05/13/2024
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives Supports expansion of Tevogen's ExacTcell™ platform toward additional clinical trials Bolsters a financial path to positive cashflow and minimizes dilution WARREN, N.J., May 10, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has entered into a binding term sheet [with an existing investor] to secure up to $50 million of financing. 05/10/2024
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives Acquire cell therapy manufacturing facility with clinical and commercial capabilities Further ExacTcell platform for additional clinical trials based on successful completion of POC Highlight full year financial results and clarify key financial items WARREN, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, announced financial results for full year 2023, business highlights, and upcoming operational objectives. 05/01/2024
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments Conversion of promissory notes into common stock removed $94.9 million in pro forma balance sheet liabilities. The converted common stock is included in the company's total 165 million outstanding shares. 04/26/2024
Tevogen Bio's Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers Tevogen's Chief Scientific Officer explains the company's oncology pipeline strategy as it relates to harnessing Cytotoxic T Lymphocytes to target cancers. 04/11/2024
Why Is Tevogen Bio (TVGN) Stock Up 46% Today? Tevogen Bio (NASDAQ: TVGN ) stock is seeing a surprising amount of movement on Thursday after the clinical-stage biotechnology company announced a new Head of Investor Relations and Corporate Development. Tapan V Shah is taking over as the new Head of Investor Relations and Corporate Development at Tevogen Bio. 04/04/2024
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development WARREN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc (‘Tevogen Bio') (Nasdaq: TVGN), a clinical-stage biotech company, announces the appointment of Tapan V Shah as Head of Investor Relations and Corporate Development. 04/03/2024
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price The shares of Series A-1 Preferred Stock will be issued in the first quarter and will be convertible at a conversion price of $10.00, as opposed to the $4. 03/28/2024
Tevogen Bio Announces Series A-1 Preferred Stock Investment The shares of Series A-1 Preferred Stock will be issued in the first quarter and will be convertible at a conversion price of $10.00, as opposed to the $4. 03/27/2024
Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant WARREN, N.J.--(BUSINESS WIRE)--Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN), today announced TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy for treatment of COVID-19 in high-risk patients and Long COVID, retains activity against the currently dominant and highly mutated JN.1 strain based on a review of this variant's protein sequences. TVGN 489 contains Cytotoxic T lymphocytes that recognize multiple SARS-CoV-2 proteins, or. 03/20/2024
Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita WARREN, N.J.--(BUSINESS WIRE)--Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN), congratulates Victor Sordillo PE, CSP, MBA, on his recent appointment as Managing Director of Risk Advisory Services at Verita CSG, Inc., a provider of holistic insurance and risk management solutions for commercial line clients. Mr. Sordillo has been a vital part of Tevogen's Board of Directors, contributing to the diversity of thought leadership within the executive team by way of expertise in leadership, risk. 03/05/2024
Mittul Mehta, Head of Tevogen's Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI WARREN, N.J.--(BUSINESS WIRE)--Tevogen Bio Holdings – Tevogen (Nasdaq: TVGN) Chief Information Officer and Head of company's Artificial Intelligence Initiative, Tevogen.ai, Mittul Mehta, has taken strides to emphasize the importance of proactive talent development for biopharmaceutical sector to allow rapid adoption of artificial intelligence (AI). In his recent seminar at the Yale School of Public Health, “Artificial Intelligence Opportunities in Healthcare,” he underscored the potential of AI. 02/27/2024
Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment WARREN, N.J.--(BUSINESS WIRE)--Tevogen Bio Holdings Inc. ('Tevogen Bio') (Nasdaq: TVGN) Tevogen's ExacTcell platform was developed to harness the killing ability of naturally occurring cytotoxic T lymphocytes (CTLs), against viral and malignant targets. TVGN 489, a CTL therapy produced by the ExactTcell platform, contains CTLs recognizing multiple protein targets across the SARS-CoV-2 genome. These cells were well tolerated in a completed proof of concept clinical trial in high-risk patients wi. 02/21/2024
Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market WARREN, N.J.--(BUSINESS WIRE)--Tevogen Bio Holdings Inc. ('Tevogen Bio') (Nasdaq: TVGN) celebrated commencement of its public trading by ringing the opening bell at the Nasdaq Stock Exchange in Times Square, New York, on February 15th, 2024. This major milestone underscored the company's commitment to its valued shareholders and its mission to develop commercially attractive, affordable, genetically unmodified off-the-shelf T cell therapies for large patient populations in virology, oncology, a. 02/17/2024
Tevogen Bio Announces $8 Million Equity Investment WARREN, N.J.--(BUSINESS WIRE)--On February 14, 2024, Tevogen Bio Holdings Inc. (the “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, entered into a securities purchase agreement with an investor pursuant to which the investor agreed to purchase shares of Series A Preferred Stock of the Company for an aggregate purchase price of $8.0 million. “We are excit. 02/15/2024

Unlock

TVGN Ratings Summary

TVGN Quant Ranking

Is Tevogen Bio Holdings Inc. (TVGN) a buy, sell, or hold?

What is Tevogen Bio Holdings Inc.'s stock price?

Is Tevogen Bio Holdings Inc. (TVGN) overvalued or undervalued?

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

Tevogen Investors Congratulate on Prestigious Recognition of Pioneering Biopharma Business Model, Breakthrough Innovations, Building Assets Estimated to Exceed $10 Billion

Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions

Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company's Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use

Tevogen CEO Reaffirms the Company's Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue Projections

Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024

Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID

Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Medical Innovation

Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation

CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

Tevogen Bio's Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health

Tevogen Bio's Founding CEO, Ryan Saadi, Expresses Conviction in Company's Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities

Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback

Tevogen Bio's R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian

Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility

Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities

Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances

Tevogen.AI Head Discusses Company's Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference

Tevogen Bio Set to Join Russell 3000® Index

Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event

Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event

Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2

Tevogen Bio Reports First Quarter 2024 Financial Results

Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives

Why Is Tevogen Bio (TVGN) Stock Up 54% Today?

Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives

Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives

Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments

Tevogen Bio's Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers

Why Is Tevogen Bio (TVGN) Stock Up 46% Today?

Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development

Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price

Tevogen Bio Announces Series A-1 Preferred Stock Investment

Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant

Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita

Mittul Mehta, Head of Tevogen's Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI

Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment

Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market

Tevogen Bio Announces $8 Million Equity Investment

Company Details

Ratings

Quant Factor Grades

Trading

Dividend Grades

Dividend

Earnings

Valuation

Growth

Performance

Momentum

Profitability

Risk

Ownership

Debt